Filing Overview
Source discrepancy: The request identifies Onconetix, Inc., but the provided Form 10-K is for Blue Water Vaccines Inc. (Nasdaq: BWV), filed for the fiscal year ended December 31, 2021 and signed March 31, 2022.
Business Context and Reporting Period
Blue Water Vaccines is a preclinical biotechnology company developing preventive vaccines for infectious diseases. Its platform uses norovirus shell and protruding-domain nanoparticles to present multiple antigens. Lead programs target universal influenza, H1 influenza, pneumococcal acute otitis media, norovirus-rotavirus gastroenteritis, and norovirus-malaria.
- All vaccine candidates remained in preclinical development; none had entered clinical trials or received regulatory approval.
- The company had no approved products, commercial product revenue, or sales and marketing infrastructure.
- Research and development is conducted primarily through third parties, including contract manufacturers and research organizations.
- The common stock began trading on Nasdaq under “BWV” on February 18, 2022, after the reporting period.
Financial Performance and Liquidity
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| General and administrative expense | $2.092 million | $1.097 million | Up 90.7% |
| Research and development expense | $1.325 million | $0.525 million | Up 152.4% |
| Total operating expenses | $3.417 million | $1.622 million | Up 110.7% |
| Net loss | $3.417 million | $1.599 million | Loss increased 113.7% |
| Net loss attributable to common stockholders | $4.045 million | $2.159 million | Loss increased |
| Basic and diluted loss per share | $1.26 loss | $0.67 loss | Loss increased |
| Net cash used in operating activities | $2.044 million | $1.730 million | Use increased |
| Cash and cash equivalents at year-end | $1.928 million | $4.309 million | Down $2.380 million |
| Working capital | Approximately $1.4 million | Not clearly provided | Not clearly provided |
| Accumulated deficit | $5.957 million | $2.539 million | Increased $3.417 million |
No debt balance is identified in the provided financial statements. Year-end current liabilities were $1.638 million, including $0.583 million of accounts payable and $1.056 million of accrued expenses. Total assets were $3.085 million and stockholders’ equity was $1.447 million.
Cash used in investing activities was $2,000, primarily for property and equipment. Cash used in financing activities was $334,000, primarily for deferred IPO costs. The company reported no off-balance-sheet arrangements.
Material Changes Versus 2020
- General and administrative expense rose by approximately $1.0 million, primarily from a $0.5 million discretionary bonus, $0.3 million of audit and accounting services, and increases in public relations, travel, and franchise tax costs.
- Research and development expense increased by approximately $0.8 million, driven by higher licensing and patent reimbursement costs, preclinical development activity, and personnel costs.
- The operating loss more than doubled as spending increased ahead of clinical development.
- Operating cash use increased by approximately $314,000, while year-end cash declined by approximately $2.4 million.
- In June 2021, the company entered into an exclusive license agreement with Cincinnati Children’s Hospital Medical Center for its virus-like-particle platform.
- The company began a second manufacturing project with Ology Bioservices, with an aggregate obligation of approximately $2.8 million plus materials and outsourced testing costs.
- A 4-for-1 stock split was completed in November 2021. Series Seed preferred stock remained outstanding at year-end but converted into 5.626 million common shares upon the February 2022 IPO.
Guidance, Outlook, Risks and Unusual Items
- Management expected operating losses and cash outflows to increase substantially as preclinical work, clinical trials, manufacturing, regulatory activities, staffing, and public-company costs expand.
- Based on year-end 2021 cash and the subsequent IPO proceeds, management estimated funding through the second quarter of 2023. Additional capital will be required for longer-term operations and certain pivotal trials.
- On February 23, 2022, the company completed an IPO of 2,222,222 shares at $9.00 per share and received approximately $17.2 million in net proceeds. It also issued warrants for 111,111 shares at an exercise price of $10.35.
- The company has substantial contingent obligations under its licenses, including potential milestone payments of up to approximately $59.75 million to CHMC, $51 million to Oxford University Innovation, and $1 million to St. Jude, plus royalties. These amounts were not accrued because achievement was not considered probable.
- The Ology manufacturing project had approximately $2.8 million of committed fees, with approximately $328,000 expensed in 2021 and approximately $164,000 in accounts payable and $115,000 in accrued expenses at year-end.
- COVID-19 caused development delays and could continue to affect suppliers, manufacturing, regulatory interactions, research timelines, and access to capital.
- The company depends heavily on licensed intellectual property and third-party research, manufacturing, and clinical capabilities. Failure to meet license milestones or payment obligations could result in loss or conversion of exclusive rights.
- Management disclosed material weaknesses in internal control over financial reporting related to insufficient accounting personnel, segregation of duties, oversight of complex transactions, and related-party transaction controls. Remediation was in progress.
- The company reported no material legal proceedings. A related-party receivable of approximately $22,000 was written off in 2021, and approximately $153,000 remained receivable from related parties at year-end, primarily consisting of CEO consulting fee prepayments.
- The independent auditor issued an unqualified opinion on the financial statements but did not audit the effectiveness of internal control over financial reporting.
Most Important Facts for Investors to Verify
- Confirm that the filing actually relates to Blue Water Vaccines Inc., not Onconetix, Inc.
- Verify the company’s preclinical status, absence of revenue, and lack of approved products or clinical trials as of December 31, 2021.
- Review the IPO proceeds, post-IPO share count, preferred-stock conversion, and representative warrants disclosed as subsequent events.
- Assess whether projected cash through the second quarter of 2023 is sufficient given planned clinical, manufacturing, and regulatory spending.
- Quantify potential dilution and financing needs, including the effects of future equity or convertible-debt financings and equity compensation.
- Review license milestone, royalty, maintenance-fee, termination, and diligence provisions, particularly the CHMC, Oxford, and St. Jude agreements.
- Monitor remediation of the disclosed material weaknesses in internal controls and related-party transaction procedures.
- Evaluate the reliability and applicability of the reported preclinical data, since the programs had not yet demonstrated safety or efficacy in human trials.